1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Island Pharmaceuticals Limited

Island Pharmaceuticals Limited

ILA.AX
Island Pharmaceuticals LimitedAU flagAustralian Securities Exchange
0.37
AUD
+0.01
- -
92.52MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
0.01
- -
Basic EPS, GAAP
-0.11
-0.03
-0.03
-0.03
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
0.88
0.17
- -
0.01
- -
Tangible Book Value per Share
0.32
0.05
0.02
0.02
- -
Basic Weighted Avg Shares
20
87
88
90
173
Sales/Revenue/Turnover
- -
- -
- -
1
- -
Operating Margin (%)
- -
- -
-26,182.25
-229.61
- -
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-3
-3
-3
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-25,580.2
-228.86
- -
Working Capital
6
4
2
2
- -
LT Debt
- -
- -
- -
- -
- -
Total Equity
6
4
2
2
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-15.86
-36.99
-430.31
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.03
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David Charles Foster
Sector
Healthcare
Industry
Biotechnology
Address
697 Burke Road Camberwell VIC Australia 3124
IPO Date
Apr 13, 2021
Website
islandpharmaceuticals.com
Similar Companies
Cotinga Pharmaceuticals Inc. (COTQF)
Intellia Therapeutics, Inc. (0JBU.L)
Verrica Pharmaceuticals Inc. (VRCA)
Neonc Technologies Holdings, Inc. (NTHI)
Landfar Bio-medicine Co., Ltd (000504.SZ)
KALA BIO, Inc. (0JQ2.L)
Business
Island Pharmaceuticals Limited (ASX:ILA) is a clinical-stage pharmaceutical company focused on developing and commercializing innovative treatments for infectious diseases and reproductive health. The company offers a pipeline of product candidates including IXP1603, a long-acting tenofovir alafenamide formulation for HIV pre-exposure prophylaxis; BUL-001, a reformulated misoprostol for reproductive health indications such as labour induction and postpartum hemorrhage prevention; and other antiviral and antimicrobial therapies targeting unmet needs in global health. Island's products emphasize reformulation technologies to improve patient compliance, efficacy, and accessibility, particularly in low- and middle-income countries. Founded in 2019 and headquartered in Sydney, Australia, the company operates primarily in Australia with clinical trials and partnerships extending to the United States, Europe, and Asia-Pacific regions. In late 2024, Island announced a strategic collaboration with a leading global health organization to advance BUL-001 into Phase III trials, alongside securing a A$10 million funding round to support pipeline expansion and manufacturing scale-up.

Company News

APIChat

  • proactiveinvestors.com

    Island Pharmaceuticals inks US Army research deal to advance Marburg antiviral program